NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

That is new to me:

Thanks DD, I wasn't aware of this:

4. Platform targets tumor vasculature (tumor-agnostic)

✅ Confirmed
Source: NCT04093323, NWBO 10-K, Kalinski publications
This platform combines a chemokine-modulating regimen (CKM) with a personalized dendritic cell vaccine to remodel the tumor microenvironment by normalizing abnormal tumor blood vessels. This enables better immune cell infiltration and improves T-cell access to tumors.

Because abnormal vasculature is a hallmark of many solid tumors, this approach is considered tumor-agnostic. The lead Phase 2 trial (NCT04093323) began in checkpoint-refractory melanoma and has been approved to expand into lung, breast, and bladder cancers.

This design supports NWBO’s strategic shift from a single-product GBM focus to a broader, multi-indication oncology platform.